



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/532,055	04/21/2005	Inger Mattsby-Baltzer	SYNE S2400.1	4089
24184	7590	06/09/2009	EXAMINER	
LYNN E BARBER			GANGLER, BRIAN J	
P O BOX 16528			ART UNIT	PAPER NUMBER
FORT WORTH, TX 76162			1645	
			MAIL DATE	DELIVERY MODE
			06/09/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/532,055

Applicant(s)

MATTSBY-BALTZER ET AL.

Examiner

Brian J. Gangle

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 30 January 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 21-24, 27-29 and 34-36 is/are pending in the application.
- 4a) Of the above claim(s) 21-23, 27, 29 and 34-36 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 24, 28 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Applicant's amendment and remarks, filed 9/11/2008 and 1/30/2009, are acknowledged. Claims 24 and 28 are amended. Claims 21-24, 27-29, and 34-36 are pending. Claims 21-23, 27, 29, and 34-36 are withdrawn as being drawn to non-elected inventions. Claims 24 and 28 are currently under examination.

Objections Withdrawn

The objection to the disclosure because in the system of binomial nomenclature used by scientists, an organism is referred to by its genus name and its species name, is withdrawn in light of applicant's amendment thereto.

The objection to claims 24 and 28 because genus and species names should be italicized, is withdrawn in light of applicant's amendment thereto.

Claim Rejections Withdrawn

The rejection of claims 24 and 28, under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement, is withdrawn in light of applicant's amendment thereto.

The rejection of claims 24 and 28 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement, is withdrawn in light of applicant's amendment thereto.

New Claim Rejections

35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 24 and 28 are rejected under 35 U.S.C. 102(b), as being anticipated by Wakshull *et al.* (PCT Publication WO 99/31510, 6/1999).

The instant claims are drawn to a method for the diagnosis of a fungal infection comprising assaying mucosal secretions or urine of a patient with suspected invasive infection with at least one antibody wherein the antibody reactive with a fungal $\beta(1-3)$ -glucan epitope and/or a fungal $\beta(1-3)$ (1-6)-glucan epitope in free form, in cell wall fragments of fungi, then evaluating the levels of glucans in the secretions or urine. Claims are also drawn to a method for detecting the presence of fungi in a human patient suspected of having an invasive infection, comprising performing an assay for the detection of $\beta(1,3)$ -glucans in a sample using a monoclonal antibody reactive with a *Candida* $\beta(1-3)$ - and/or a $\beta(1-3)$ (1-6)-glucan epitope in free form, or in cell wall fragments of *Candida*.

Wakshull *et al.* disclose a method of diagnosis of fungal infection where a sample is obtained from an individual and said sample is assayed, with monoclonal antibodies for the presence of $\beta(1,3)$ -glucans, which would be indicative of infection (see page 19, lines 1-10 and 19-25). The biological sample can be human urine, and said antibodies can bind to $\beta(1,3)$ -glucans from *Candida albicans* (see figures 7-8).

Conclusion

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian J. Gangle whose telephone number is (571)272-1181. The examiner can normally be reached on M-F 7-3:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert Mondesi can be reached on 571-272-0956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Brian J Gangle/
Examiner, Art Unit 1645

/Robert B Mondesi/
Supervisory Patent Examiner, Art Unit 1645